寶沙發展(01069.HK)擬斥近713萬人幣購內地西洋參產品加工及分銷商52%股權 續停牌
寶沙發展(01069.HK)公佈,向深圳佳士森之直接全資附屬陝西佳仕森藥業投資,收購目標公司留壩縣佳仕森中藥綜合開發之52%股權,代價爲712.87萬元人民幣(約766.52萬港元)。
目標公司爲一間於中國成立的有限公司,主要業務包括加工及分銷一系列西洋參產品。
公司股份已自今年8月17日起於聯交所暫停買賣,並將繼續暫停,以待刊發提供收購事項詳情之公告。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.